SCHEMBL2961780

SCHEMBL2961780

Cc1ccc2c(Nc3cc(N(C)C(=O)O)ccc3Sc3ccccc3)ccnc2n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.39
AKT2 P31751 1/20 0.39
MAPT P10636 3/20 0.37
LMNA P02545 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
EGFR P00533 1/20 0.34
PRKCA P17252 1/20 0.34
ALDH1A1 P00352 3/20 0.34
NPSR1 Q6W5P4 2/20 0.34
HPGD P15428 2/20 0.34
POLB P06746 2/20 0.34
SRC P12931 1/20 0.32
GSK3B P49841 1/20 0.32
AURKB Q96GD4 1/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
ADORA2A P29274 2/20 0.32
ADORA1 P30542 2/20 0.32
TDP1 Q9NUW8 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2018796 0.83 PIM1 (0.42) PIM1AKT2MAPTLMNASMN1; SMN2
SCHEMBL2969129 0.82 ABCG2 (0.42) PIM1AKT2MAPTLMNASMN1; SMN2
SCHEMBL13273825 0.82 PIM1 (0.41) PIM1AKT2MAPTLMNASMN1; SMN2
SCHEMBL2054424 0.82 PIM1 (0.39) PIM1AKT2MAPTLMNASMN1; SMN2
SCHEMBL2961779 0.81 PIM1 (0.41) PIM1AKT2MAPTLMNASMN1; SMN2
SCHEMBL2971914 0.81 PIM1 (0.45) PIM1AKT2MAPTLMNASMN1; SMN2
SCHEMBL2960981 0.81 PIM1 (0.43) PIM1AKT2MAPTLMNASMN1; SMN2
SCHEMBL13273746 0.80 PIM1 (0.40) PIM1AKT2MAPTLMNASMN1; SMN2
SCHEMBL15919130 0.80 PIM1 (0.37) PIM1AKT2EGFRADORA2AADORA1
SCHEMBL2968817 0.80 TDP1 (0.43) PIM1AKT2MAPTLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338605-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2012-12-25 US disclosed
US-8236950-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2012-08-07 US disclosed
US-20100256139-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2010-10-07 US disclosed
EP-1979349-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2010-07-28 EP disclosed
US-7763731-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2010-07-27 US disclosed
EP-2094276-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2009-09-02 EP disclosed
WO-2008133753-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2008-11-06 WO disclosed
EP-1979349-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-10-15 EP disclosed
US-20070232645-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed
WO-2007076035-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232645-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 PIM1 2963/4885AKT2 3903/4885MAPT 1347/4885
US-20100256139-A1 Anti-Viral Compounds HAVCR2, MAVS, EIF2AK2 PIM1 2963/4885AKT2 3903/4885MAPT 1347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.